Mirabegron vs. placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: A safety analysis from the PLUS study

Authors
Category Primary study
JournalCanadian urological association journal
Year 2020
This article has no abstract
Epistemonikos ID: 39151c94cd3167ef358a949ed374daa6ba11771f
First added on: Apr 29, 2024